In this editorial, we offer a summary of the risk associated with hepatitis B reactivation (HBVr) in the setting of both solid and hematologic malignancies treated with Bruton tyrosine kinase (BTK) inhibitors, with insights derived from current studies. Furthermore, we emphasize the critical need for a framework regarding robust risk evaluation in patients undergoing such treatments. This framework is essential for identifying those at increased risk of HBVr, enabling healthcare providers to implement proactive measures to prevent reactivation and ensure the safe administration of BTK inhibitor therapy.
All Keywords
【저자키워드】 hematologic malignancies, solid tumors, Bruton tyrosine kinase inhibitors, Hepatitis B virus reactivation, Prophylaxis guidelines,
【저자키워드】 hematologic malignancies, solid tumors, Bruton tyrosine kinase inhibitors, Hepatitis B virus reactivation, Prophylaxis guidelines,